Segment Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) segment	Jun. 30, 2022 USD ($)
Results of operations by reportable segment
Net sales	$ 1,994,011	$ 4,186,516	$ 4,511,983	$ 6,651,685
Cost of goods sold	513,857	649,220	1,064,599	1,121,560
Selling, general and administrative expenses	2,249,592	3,216,604	4,380,231	7,114,342
Gain on settlement with Vivus				(3,389,941)
Research and development expenses	866,575	421,242	1,185,668	826,602
Depreciation and amortization expense	826,795	1,560,870	1,653,590	3,121,740
Change in fair value of derivative liability				(460,000)
Interest income	(52,924)		(119,241)
Interest expense	136,799	150,372	278,966	303,398
Net loss	(2,546,683)	(1,811,792)	$ (3,931,830)	(1,986,016)
Operating segments
Segment Information
Number of Operating Segments | segment			2
Corporate
Results of operations by reportable segment
Selling, general and administrative expenses	1,509,875	1,266,508	$ 2,719,796	2,789,636
Change in fair value of derivative liability				(460,000)
Interest income	(52,924)		(119,241)
Interest expense	136,799	150,372	278,966	303,398
Net loss	(1,593,750)	(1,416,880)	(2,879,521)	(2,633,034)
Prescription Medications | Operating segments
Results of operations by reportable segment
Net sales	984,408	3,332,173	2,490,686	4,856,941
Cost of goods sold	83,451	350,826	257,721	489,007
Selling, general and administrative expenses	258,145	1,729,149	754,993	3,440,168
Gain on settlement with Vivus				(3,389,941)
Research and development expenses	865,122	344,936	1,130,338	750,296
Depreciation and amortization expense	575,470	1,269,665	1,150,939	2,539,328
Net loss	(797,780)	(362,403)	(803,305)	1,028,083
Medical Devices | Operating segments
Results of operations by reportable segment
Net sales	1,009,603	854,343	2,021,297	1,794,744
Cost of goods sold	430,406	298,394	806,878	632,553
Selling, general and administrative expenses	481,572	220,947	905,442	884,538
Research and development expenses	1,453	76,306	55,330	76,306
Depreciation and amortization expense	251,325	291,205	502,651	582,412
Net loss	$ (155,153)	$ (32,509)	$ (249,004)	$ (381,065)